DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging

Steroids

Volumn 63, Issue 5-6, 1998, Pages 322-328

  Labrie, Fernand ^a   Bélanger, Alain ^b   Luu The, Van ^b   Labrie, Claude ^b   Simard, Jacques ^b   Cusan, Leonello ^b   Gomez, Jose Luis ^b   Candas, Bernard ^b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

Adrenals; Androgens; DHEA; Estrogens; Intracrinology; Menopause; Peripheral target tissues; Steroidogenesis

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANDROGEN; ANDROSTENEDIONE; ANTIESTROGEN; ESTROGEN; ESTRONE; GESTAGEN; HYDROXYPROLINE; OSTEOCALCIN; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ANIMAL MODEL; BREAST CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; STEROID METABOLISM; STEROIDOGENESIS; TARGET ORGAN;

AGING; ANDROGENS; ANIMALS; BREAST NEOPLASMS; CELL DIVISION; DEHYDROEPIANDROSTERONE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED;

ANIMALIA; MUS MUSCULUS; PRIMATES;

EID: 0032076761     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00007-5     Document Type: Conference Paper

References (36)

1. 1. Labrie C, Bélanger A, Labrie F (1988). Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123:1412-1417.
2. 2. Labrie F (1991). Intracrinology. Mol Cell Endocrinol 78:C113-C118.
3. 3. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G (1992). Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classic and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol 43:805-826.
4. 4. Luu-The V, Zhang Y, Poirier D, Labrie F (1995). Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol 55:581-587.
5. 5. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, et al. (1997). The key role of 17β-HSDs in sex steroid biology. Steroids 62:148-158.
6. 6. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G, Morel Y, et al. (1996). The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency In: Hansson V, Levy FO, Taskén K (eds), Signal Transduction in Testicular Cells Ernst Schering Research Foundation Workshop Springer-Verlag, Berlin, Heidelberg, New York, pp. 185-218.
7. 7. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C (1995). DHEA and peripheral androgen and estrogen formation: Intracrinology. Ann NY Acad Sci 774:16-28.
8. 8. Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, et al. (1994). Changes in serum concentrations of conjugated and unconjugated steroids in 40-to 80-year-old men. J Clin Endocrinol Metab 79:1086-1090.
9. 9. Vermeulen A, Verdonck L (1976). Radioimmunoassays of 17β-hydroxy-5α-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17β-hydroxyprogesterone and progesterone and its application to human male plasma. J Steroid Biochem 7:1-10.
10. 10. Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabchi AE, Buster JE, et al. (1988). Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 66:1329-1331.
11. 11. Nestler JE, Barlascini CO, Clore JN, Blackard WG (1988). Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66:57-61.
12. 12. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK (1981). Abnormal 24-hr mean plasma concentrations of dehydroepiandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 41:3360-3363.
13. 13. Stahl F, Schnorr D, Pilz C, Dorner G (1992). Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol 99:68-70.
14. 14. Schwartz AG, Pashko L, Whitcomb JM (1986). Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 14:357-362.
15. 15. Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, et al. (1993). Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 169:1536-1539.
16. 16. Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994). Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-1367.
17. 17. Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F (1996). Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol 150:S43-S50.
18. 18. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A (1997). Effect of 12-month DHEA replacement therapy on bone, vaginum, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82:3498-3505.
19. 19. Labrie F (1993). Intracrinology: its impact on prostate cancer. Curr Opin Urol 3:381-387.
20. 20. Labrie F, Dupont A, Simard J, Luu-The V, Bélanger A (1993). Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 24(Suppl. 2):94-105.
21. 21. Labrie C, Martel C, Dufour JM, Lévesque C, Mérand Y, Labrie F (1992). Novel compounds inhibit estrogen formation and action. Cancer Res 52:610-615.
22. 22. Luo S, Sourla A, Bélanger A, Gauthier S, Mérand Y, Labrie F (1996). Effect of 24-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. In: Proceedings of 10th International Congress of Endocrinology, San Francisco Endocrine Society. pp Abst. pp. 1-68, 151 (abst.).
23. 23. Labrie F, Dupont A, Bélanger A (1985). Complete androgen blockade for the treatment of prostate cancer In: de Vita VT, Hellman S, Rosenberg SA (eds), Important Advances in Oncology. JB Lippincott, Philadelphia, pp. 193-217.
24. 24. Bolander FF (1996). Introduction In: Molecular Endocrinology Academic Press, San Diego, London, pp. 1-23.
25. 25. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B (1997). Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82:2396-2402.
26. 26. Johnston CC Jr, Epstein S (1981). Clinical, biochemical, radiographic, epidemiologic, and economic features of osteoporosis. Ortho Clin North Am. 12:559-569.
27. 27. Bardon S, Vignon F, Chalbos D, Rochefort H (1985). RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab. 60:692-697.
28. 28. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1589-1593.
29. 29. Franceschi S (1990). The epidemiology of endometrial cancer. Gynecol Oncol. 41:1-16.
30. 30. Friedl A, Jordan VC (1994). What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31:27-39.
31. 31. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenne PF, et al. (1982). Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144:511-518.
32. 32. Lobo RA (1987). Absorption and metabolic effects of different types of estrogens and progestrogens. Obstet Gynecol Clin North Am. 14:143-167.
33. 33. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, et al. (1997). (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J Med Chem. 40:2117-2122.
34. 34. Luo S, Martel C, Sourla A, Gauthier S, Mérand Y, Bélanger A, et al. (1997). Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer 73:381-391.
35. 35. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Mérand Y, et al. (1997). Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57:3494-3497.
36. 36. Labrie F, Bélanger A, Cusan L, Candas B (1997). Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab. 82:2403-2409.